Intravesical instillation of adriamycin for bladder tumors.
In the present series of trials, Adriamycin (ADM) intravesical instillation therapy was found to be effective against tumors of papillary morphology measuring less than 10 mm in diameter that were of low pathological stage and low histological grade. The rate of complete disappearance increased in proportion to the concentration of ADM and the duration of retention of the drug, although the efficacy rates were almost the same in each trial. On the other hand, side effects on the bladder were reduced when the instilled solution was lower in concentration and the retention time was short.
Ohe
H
H
Dept. of Urology, Kyoto Prefectural University of Medicine, Japan.
Watanabe
H
H
Mishina
T
T
Kojima
M
M
Nakagawa
S
S
D000283:Administration, Intravesical; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000627:therapeutic use; D006801:Humans; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D015251:Epirubicin; D004317:Doxorubicin; C027260:pirarubicin